Oncology Pharma Inc.

​

July 20, 2021

​

Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP

​

June 30, 2021

 

Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase

 

June 15, 2021

 

Oncology Pharma, Inc. Eyes Collaboration with Patent Opportunities Amongst Its Licensed Intellectual Properties

​

June 9, 2021

 

Oncology Pharma and Ribera Solutions Release White Paper Regarding Patient Engagement and Retention Platfomr

 

 

May 18, 2021

 

Oncology Pharma, Inc. Is Pursuing the Development of its Small Molecule Drug for the Treatment of Colon Cancer

 

 

May 7, 2021

​

Oncology Pharma Enters into License Agreement for Small Molecules Intellectual Property for the Treatment of Colon Cancer

​

April 21, 2021

​

Oncology Pharma, Inc. Prepares Plan Toward Funding Development and Implementation of Ribera Solutions' Patient Engagement and Retention Platform

 

April 14, 2021

 

Oncology Pharma, Inc. Addresses Pancreatic Cancer, the Need for an Effective Therapy and the Potential of mRNA Technology

 

April 7, 2021

 

Oncology Pharma Signs License Agreement for mRNA Intellectual Property As It Reveals Strategic Plans for Treating Pancreatic Cancer

 

March 31, 2021

 

Oncology Pharma Has Provided Initial Funding to NanoSmart Pharmaceuticals to Conduct Feasibility Studies for Initial Phases of IND-Enabling Activities

 

March 16, 2021

 

Oncology Pharma Reveals Strategic Plans for Company Growth and Focus

 

March 10, 2021

 

Oncology Pharma, Inc. Vetting CROs to Develop Research Plan and Indications for Recently Licensed Cancer Combination Therapy

 

March 4, 2021

 

Oncology Pharma Moves to Fund Lead Drug Formulation & IND-Enabling Studies

​

​

 

 

February 26, 2021

​

Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent

​

February 22, 2021

​

Oncology Pharma Extends Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Veterinary Oncology

​

​

February 16, 2021

​

Oncology Pharma is Pleased to Welcome New Chairman to its Scientific Advisory Board

 

​

February 9, 2021

​

Oncology Pharma Renews Licensing Agreement with Ribera Solutions LLC for its Connect2Med Clinical Trials Platform

 

 

February 3, 2021

​

Oncology Pharma Extends its Licensing Agreement with NanoSmart Pharmaceuticals, Inc. for Human Oncology

​

​

January 28, 2021

​

Oncology Pharma Announces the Appointment of New Chief Financial Officer

 

August 27, 2020

​

Oncology Pharma Announces Extension of Letter of Intent with Kalos Therapeutics, Retained an Interim CEO and Approval of Reverse Stock Split

 

 

April 21, 2020

​

Oncology Pharma Licensor and Co-Development Partner, Kalos Therapeutics, Announces Progress in Covid-19 Preventative & Therapeutic Approaches

​

April 6, 2020

​

Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19

​

​

March 11, 2020

 

Oncology Pharma Continues Licensing Agreement with NanoSmart

 

 

January 28, 2020

​

Oncology Pharma, Inc. Narrows Focus on Funding Efforts

​

​

2019

 

December 26, 2019

​

Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Investment Partners, Ltd.